Skip to main content
. 2022 Oct 29;13(10):910. doi: 10.1038/s41419-022-05354-y

Fig. 2. EGFL7 promotes resistance to EGFR inhibitors in acquired resistance phase.

Fig. 2

Survival curve of osimertinib-resistant PC9 (PC9OR) cells with the indicated si-RNAs (A) or sh-RNAs (B) in different concentration of osimertinib treatment for 72 h. Data present as average of four identically wells of percentage of surviving cells to 6 wells of vehicle-treated control. C Cell cycle distribution of PC9OR cells with the indicated sh-RNAs treated with 2 µM osimertinib or vehicle. Data present as mean ± standard deviation (SD) of three biological replicates. D Growth curves of tumor xenografts derived from EGFL7-knockdown PC9OR cells or control cells treated with 3 mg/kg Osimertinib. E Images of the indicated xenograft tumors (upper panel) and statistical analysis of tumor weight (lower panel). F Left panel showing the representative images of Ki67 staining in the indicated xenograft tumors, and right panel showing statistical analysis of the percentage of Ki67 positive cells. Scale bar: 200 µm. The data in right panel (F) are average value of three biological replicates. The data in E are average value of five biological replicates. The median line in E represents median values. The top and bottom of box in E are 25th and 75th percentiles. Data in A, B, D–F are shown as mean ± standard error of the mean (SEM). p values in A, B, D are calculated by two way ANNOVA. p values in E and F are calculated by unpaired two-tailed Student’s t test (*p < 0.05; ***p < 0.001).